The Optimizing Pediatric HIV-1 Therapy (OPH) Project
PDF version

Dr. Dalton Wamalwa, PI
Project is a collaborative study conducted by the University of Nairobi Department of Paediatrics and Child Health and the University of Washington department of Global Health. The objectives of the OPH study are:
Primary Objective
To compare growth and morbidity in infants (who initiated HAART at <12 months of age with subsequently normalized CD4% and growth following 24 months of HAART) randomized to deferred versus continuous therapy and followed for an additional 18 months.
Secondary Objective
To determine predictors of non-progression of HIV among the infants, including: age, adherence, HIV-1 specific immune responses, baseline HIV-1 RNA, CD4 percent and immune activation.
Funding: The OPH study is funded by the National Institutes of Health (2 RO1 HD023412-6). Administrative structure: The OPH study at the University of Nairobi is led by the site principal investigator , Dr Dalton Wamalwa, Senior lecturer department of Paediatrics. The study has 11 contract staff